These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15741265)

  • 1. Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients.
    Lesueur F; Cebrian A; Cranston A; Leyland J; Faid TM; Clements MR; Robledo M; Whittaker J; Ponder BA
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3454-7. PubMed ID: 15741265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
    Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G; Saeger HD; Roesner D; Schackert HK
    Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].
    Frank-Raue K; Heimbach C; Rondot S; Usadel KH; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
    Dtsch Med Wochenschr; 2003 Sep; 128(39):1998-2002. PubMed ID: 14508694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The familial medullary thyroid carcinoma-associated RET E768D mutation in a multiple endocrine neoplasia type 2A case.
    Aiello A; Cioni K; Gobbo M; Collini P; Gullo M; Della Torre G; Passerini E; Ferrando B; Pilotti S; Pierotti MA; Pasini B
    Surgery; 2005 May; 137(5):574-6. PubMed ID: 15855933
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
    Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
    Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of patients with hereditary medullary thyroid carcinoma.
    Fitze G
    Eur J Pediatr Surg; 2004 Dec; 14(6):375-83. PubMed ID: 15630638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET codon 804 mutations in multiple endocrine neoplasia 2: genotype-phenotype correlations and implications in clinical management.
    Mukherjee S; Zakalik D
    Clin Genet; 2011 Jan; 79(1):1-16. PubMed ID: 20497437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.
    Jimenez C; Habra MA; Huang SC; El-Naggar A; Shapiro SE; Evans DB; Cote G; Gagel RF
    J Clin Endocrinol Metab; 2004 Aug; 89(8):4142-5. PubMed ID: 15292360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of mutations in the RET proto-oncogene in patients with medullary thyroid tumor].
    Amosenko FA; Brzhezovskiĭ VZh; Liubchenko LN; Shabanov MA; Kozlova VM; Vanushko VE; Kazubskaia TP; Gar'kavtseva RF; Kalinin VN
    Genetika; 2003 Jun; 39(6):847-54. PubMed ID: 12884527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
    Marsh DJ; Andrew SD; Eng C; Learoyd DL; Capes AG; Pojer R; Richardson AL; Houghton C; Mulligan LM; Ponder BA; Robinson BG
    Cancer Res; 1996 Mar; 56(6):1241-3. PubMed ID: 8640806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine.
    Schuffenecker I; Virally-Monod M; Brohet R; Goldgar D; Conte-Devolx B; Leclerc L; Chabre O; Boneu A; Caron J; Houdent C; Modigliani E; Rohmer V; Schlumberger M; Eng C; Guillausseau PJ; Lenoir GM
    J Clin Endocrinol Metab; 1998 Feb; 83(2):487-91. PubMed ID: 9467562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
    Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
    Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma.
    Elston MS; Meyer-Rochow GY; Holdaway I; Conaglen JV
    Horm Metab Res; 2012 May; 44(5):339-42. PubMed ID: 22274720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma.
    Huang SC; Torres-Cruz J; Pack SD; Koch CA; Vortmeyer AO; Mannan P; Lubensky IA; Gagel RF; Zhuang Z
    J Clin Endocrinol Metab; 2003 Jan; 88(1):459-63. PubMed ID: 12519890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.